Alien Registration- Lerman, Sam (Portland, Cumberland County)

https://digitalmaine.com/alien_docs/31992/thumbnail.jp

Consciousness

There are many bodies, neurons, interacting in a brain. For bodies and interactions to produce consciousness might depend on specific matter and matter interactions, such as specifically those of the neural grey matter and voltages of the brain, or abstract representations and information patterns, such as just the neural firing patterns or those that can be simulated on GPUs. My flipbook thought experiment, elaborated on later in this work, reduces the latter possibility to absurdity. We're able to feel complex emotional experiences at the same time, and observe many concurrent phenomena, including, for example, the visual image before our eyes. This singular observation might be an illusion, or might be a literal singularization of phenomena into a single observer. My physics explanation for how this singularization might happen, elaborated on later in this work, is evidenced by a measured phenomenon in standard physics. Thus, the best explanation for consciousness remaining will be specific physical matter and modes of interactions (via biological neurons and reactions) and singularization (via my hypothesized physics theory, lacking any other). Then one more point is made about how assuming consciousness as a fundamental property of the universe leads to a new answer to the mystery of cosmogenesis. That answer is specified. Finally, all of this together paints a strongly evidenced theory of consciousness, as well as cosmogenesis, whose alternatives have much less justification

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Alien Registration- Lerman, Sam (Portland, Cumberland County)

https://digitalmaine.com/alien_docs/31992/thumbnail.jp